| Careers | Contact Us

2018 Press releases
E-mail Alerts Receive e-mail alerts | RSS Rss feeds
Keyword search
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
11/08/18BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial UpdatePrinter Friendly Version
11/01/18BioLineRx to Report Third Quarter 2018 Results on November 8, 2018Printer Friendly Version
10/20/18BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 CongressPrinter Friendly Version
10/19/18BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 CongressPrinter Friendly Version
10/03/18BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology IndicationsPrinter Friendly Version
08/30/18BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New YorkPrinter Friendly Version
08/13/18BioLineRx Reports Second Quarter 2018 Financial ResultsPrinter Friendly Version
08/07/18BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell MobilizationPrinter Friendly Version
08/06/18BioLineRx to Report Second Quarter 2018 Results on August 13, 2018Printer Friendly Version
08/01/18BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid TumorsPrinter Friendly Version
07/30/18BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic CancerPrinter Friendly Version
06/18/18BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML PatientsPrinter Friendly Version
06/13/18BioLineRx to Participate at JMP Securities 2018 Life Sciences ConferencePrinter Friendly Version
05/22/18BioLineRx Reports First Quarter 2018 Financial ResultsPrinter Friendly Version
05/17/18BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML PatientsPrinter Friendly Version
05/17/18BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow TransplantationPrinter Friendly Version
05/16/18BioLineRx to Report First Quarter 2018 Results on May 22, 2018Printer Friendly Version
05/16/18BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid LeukemiaPrinter Friendly Version
03/26/18BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid TumorsPrinter Friendly Version
03/14/18BioLineRx to Present at the 28th Annual Oppenheimer Healthcare ConferencePrinter Friendly Version
03/06/18BioLineRx Reports Year End 2017 Financial ResultsPrinter Friendly Version
02/27/18BioLineRx to Report Annual 2017 Results on March 6, 2018Printer Friendly Version
02/06/18BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13Printer Friendly Version
01/23/18BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cellsPrinter Friendly Version
01/23/18BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical StudiesPrinter Friendly Version
01/17/18BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic CancerPrinter Friendly Version

Interview with Philip Serlin, CEO
December 2016